Kenvue Inc. (NYSE:KVUE) Stake Raised by Quantinno Capital Management LP

Quantinno Capital Management LP increased its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 168.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 81,314 shares of the company's stock after buying an additional 51,016 shares during the quarter. Quantinno Capital Management LP's holdings in Kenvue were worth $1,881,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KVUE. Riverview Trust Co purchased a new position in shares of Kenvue in the 3rd quarter valued at $30,000. Ashton Thomas Securities LLC purchased a new stake in shares of Kenvue in the third quarter worth about $35,000. Studio Investment Management LLC grew its stake in shares of Kenvue by 52.1% in the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company's stock valued at $45,000 after buying an additional 845 shares in the last quarter. Deseret Mutual Benefit Administrators raised its holdings in shares of Kenvue by 49.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company's stock valued at $45,000 after buying an additional 651 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in Kenvue in the 2nd quarter worth approximately $61,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on KVUE. JPMorgan Chase & Co. boosted their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Piper Sandler lifted their target price on Kenvue from $20.00 to $21.00 and gave the stock a "neutral" rating in a research report on Monday, September 23rd. Royal Bank of Canada raised Kenvue from a "hold" rating to a "moderate buy" rating in a report on Monday. Jefferies Financial Group started coverage on Kenvue in a research report on Tuesday, September 24th. They issued a "buy" rating and a $27.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a "buy" rating to a "hold" rating and decreased their price target for the stock from $25.00 to $24.00 in a research report on Thursday. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and a consensus target price of $22.64.

Kenvue Stock Performance

Shares of NYSE:KVUE traded up $0.10 on Thursday, reaching $22.32. 14,894,078 shares of the company's stock were exchanged, compared to its average volume of 17,674,957. The business's 50-day moving average is $22.95 and its two-hundred day moving average is $21.17. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The firm has a market capitalization of $42.79 billion, a price-to-earnings ratio of 40.58, a PEG ratio of 2.07 and a beta of 1.36.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. The firm had revenue of $3.90 billion for the quarter, compared to analysts' expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Kenvue's revenue was down .4% on a year-over-year basis. During the same quarter last year, the company posted $0.31 earnings per share. As a group, equities research analysts forecast that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.67%. The ex-dividend date was Wednesday, November 13th. Kenvue's dividend payout ratio is presently 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.